Palbociclib
99%
- Product Code: 54571
CAS:
571190-30-2
| Molecular Weight: | 447.54 g./mol | Molecular Formula: | C₂₄H₂₉N₇O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | room temperature, dry |
Product Description:
Palbociclib is primarily used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is often prescribed in combination with other medications, such as letrozole or fulvestrant, to enhance its effectiveness. The drug works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which play a crucial role in cell division and cancer progression. By blocking these enzymes, palbociclib helps to slow down or stop the growth of cancer cells, thereby improving progression-free survival in patients. It is particularly beneficial for postmenopausal women with advanced breast cancer, offering a targeted therapy option that can be less harsh than traditional chemotherapy. Regular monitoring of blood counts is essential during treatment, as palbociclib can lower white blood cell levels, increasing the risk of infections.
Product Specification:
| Test | Specification |
|---|---|
| Purity | 98.5 |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.025 | 10-20 days | $15.78 |
+
-
|
| 0.100 | 10-20 days | $27.41 |
+
-
|
| 0.500 | 10-20 days | $91.36 |
+
-
|
| 1.000 | 10-20 days | $164.45 |
+
-
|
| 5.000 | 10-20 days | $738.39 |
+
-
|
Palbociclib
Palbociclib is primarily used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is often prescribed in combination with other medications, such as letrozole or fulvestrant, to enhance its effectiveness. The drug works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which play a crucial role in cell division and cancer progression. By blocking these enzymes, palbociclib helps to slow down or stop the growth of cancer cells, thereby improving progression-free survival in patients. It is particularly beneficial for postmenopausal women with advanced breast cancer, offering a targeted therapy option that can be less harsh than traditional chemotherapy. Regular monitoring of blood counts is essential during treatment, as palbociclib can lower white blood cell levels, increasing the risk of infections.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :